Skip to main content
SpringerLink
Log in

Nursing Home-Acquired Pneumonia

Treatment Options

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Nursing home-acquired pneumonia (NHAP) is a diagnostic and therapeutic challenge, and antimicrobial therapy represents only 1 facet of the treatment of this disease. The nursing home population consists of a mixture of well, frail and dependent elderly. For some residents, supportive care may be the best therapeutic option.

A variety of antimicrobial regimens have been proposed for the empirical therapy of NHAP; however, there are still very few data from controlled clinical trials that assess outcome. The clinical trials that have been completed support the concept that an early switch from intravenous to oral therapy can be successfully used to treat pneumonia affecting frail, often seriously ill, groups of patients.

Annual influenza vaccine should be offered to all nursing home residents. This practice is about 50% effective in preventing hospitalisation and pneumonia, and about 80% effective in preventing death. The same level of evidence is not available to support the use of pneumococcal vaccine in this group; however, current practice suggests that all nursing home residents receive this vaccine on admission and once every 6 years thereafter.

Frequently, knowledge about pneumonia is not applied as optimally as should be done. Care maps have been shown to reduce length of stay and shorten the time from emergency room entry until administration of antibiotic therapy by up to 3 hours.

Areas for urgent research attention in patients with NHAP are: (a) proper studies to define the microbiological aetiology of NHAP (this requires bron-choscopy with sampling of the distal airways using a protected bronchial brush); (b) randomised controlled clinical trials of sufficient size to determine whether one antibiotic regimen is superior to another (currently most trials are designed to show that the agent under study is equivalent to a currently used agent); and (c) end-of-life decision making in the nursing home population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Olive KE, Berk SL. Infection in the nursing home. Clin Geriatr Med 1992; 8: 821–34

    PubMed  CAS  Google Scholar 

  2. Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Respir Infect 1990; 5: 260–8

    PubMed  CAS  Google Scholar 

  3. Marrie TJ, Durant J, Kwan C. Nursing home-acquired pneumonia: a case-control study. J Am Geriatr Soc 1986; 34: 697–702

    PubMed  CAS  Google Scholar 

  4. Garb JL, Brown RB, Garb JR, et al. Differences in etiology of pneumonias in nursing home and community patients. JAMA 1978; 240: 2169–72

    Article  PubMed  CAS  Google Scholar 

  5. Marrie TJ, Durant H, Yates L. Community acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989 Jul-Aug; 11(4): 586–99

    Article  PubMed  CAS  Google Scholar 

  6. Phillips SL, Branaman-Phillips J. The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia. J Am Geriatr Soc 1993; 41: 1071–4

    PubMed  CAS  Google Scholar 

  7. Drinka PJ, Gauerke C, Voeks S, et al. Pneumonia in a nursing home. J Gen Intern Med 1994; 9: 650–2

    Article  PubMed  CAS  Google Scholar 

  8. Chow CW, Senathiragah N, Rawji M, et al. Interim report on drug utilization review of community-acquired and nosoco-mial pneumonia: clinical bacteriological and radiological spectrum. Can J Infect Dis 1994; 5 Suppl. C: 20C–27C

    Google Scholar 

  9. Morris J. Physiological changes due to age: implications for respiratory drug therapy. Drugs Aging 1994; 4(3): 207–20

    Article  PubMed  CAS  Google Scholar 

  10. Holas MA, DePippo KL, Reading MJ. Aspiration and relative risk of medical complications following stroke. Arch Neurol 1994; 51: 1501–3

    Article  Google Scholar 

  11. Kilkuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251–3

    Google Scholar 

  12. Horner J, Alberts MJ, Davison DN, et al. Swallowing in Alzheimer’s disease. Alzheimer Dis Assoc Disord 1994; 8: 177–89

    Article  PubMed  CAS  Google Scholar 

  13. Fein AM. Pneumonia in the elderly: special diagnostic and therapeutic considerations. Med Clin North Am 1994 Sep; 78: 1015–33

    PubMed  CAS  Google Scholar 

  14. Terpenning MS, Bradley SF, Wan JY, et al. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc 1994; 42: 1062–9

    PubMed  CAS  Google Scholar 

  15. Valenti WM, Trudel RG, Bentley DW. Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. N Engl J Med 1978; 298: 1108–11

    Article  PubMed  CAS  Google Scholar 

  16. Falsey AE, Treanor JJ, Betts RF, et al. Viral respiratory infections in the institutionalized elderly: clinical and epidemio-logic findings. J Am Geriatr Soc 1992; 40: 115–9

    PubMed  CAS  Google Scholar 

  17. Mehr DR, Foxman B, Colombo P. Risk factors for mortality from lower respiratory infections in nursing home patients. J Fam Pract 1992; 34: 585–91

    PubMed  CAS  Google Scholar 

  18. Ainslie N, Beisecker AE. Changes in decisions by elderly persons based on treatment description. Arch Intern Med 1994 Oct 10; 154: 2225–33

    Article  PubMed  CAS  Google Scholar 

  19. Tresch DD, Neahring JM, Duthie EH, et al. Outcomes of car-diopulmonary resuscitation in nursing homes: can we predict who will benefit?. Am J Med 1993; 95: 123–30

    Article  PubMed  CAS  Google Scholar 

  20. Tsevan J, Cook F, Green ML, et al. Health values of the seriously ill. Ann Intern Med 1994; 122: 514–20

    Google Scholar 

  21. British Thoracic Society and Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med 1987; 62: 195–220

    Google Scholar 

  22. Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994; 9: 140–52

    PubMed  CAS  Google Scholar 

  23. Norman DC. Pneumonia in the elderly: empiric antimicrobial therapy. Geriatrics 1991 Dec; 46: 26–32

    PubMed  CAS  Google Scholar 

  24. Mulligan T. Parenteral antibiotic therapy for patients in nursing homes. Rev Infect Dis 1991; 13 Suppl. 2: S180–3

    Article  PubMed  Google Scholar 

  25. Mandell LA, Niederman M, The Canadian Community Acquired Pneumonia Consensus Conference Group. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Can J Infect Dis 1993 Jan/Feb; 4(1): 25–8

    PubMed  CAS  Google Scholar 

  26. Lefevre F, Feinglass J, Potts S, et al. Iatrogenic complications in higher-risk, elderly patients. Arch Intern Med 1992 Oct; 152: 2074–80

    Article  PubMed  CAS  Google Scholar 

  27. Esposito AL. Pneumonia in the elderly. Am Fam Physician 1989; 40 Suppl. 5: 23S–32S

    PubMed  CAS  Google Scholar 

  28. Donowitz GR, Mandell GL. Drug therapy: betalactam antibiotics (1). N Engl J Med 1988; 318(7): 419–26

    Article  PubMed  CAS  Google Scholar 

  29. Donowitz GR, Mandell GL. Drug therapy: betalactam antibiotics (2). N Engl J Med 1988; 318(8): 490–500

    Article  PubMed  CAS  Google Scholar 

  30. Mandigers CMPW, Diepersloot RJA, Dessens M, et al. A hospital outbreak of penicillin-resistant pneumococci in the Netherlands. Eur Respir J 1994; 7: 1635–9

    Article  PubMed  CAS  Google Scholar 

  31. Mandell LA. Antibiotics for pneumonia therapy. Med Clin North Am 1994 Sep; 78(5): 997–1013

    PubMed  CAS  Google Scholar 

  32. Goldstein EJC, Citron DM. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococ-cus epidermidis, and methicillin-susceptible and resistant and tolerant and non-tolerant Staphylococcus aureus. Antimicrob Agents Chemother 1985 Jul; 28(1): 160–2

    Article  PubMed  CAS  Google Scholar 

  33. Foran RM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. DICP 1991; 25: 546–52

    PubMed  CAS  Google Scholar 

  34. Choo U. UK revises indications for co-trimoxazole. Lancet 1995 Jul 15; 346: 175

    Article  Google Scholar 

  35. Wiseman LR, Balfour JA. Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 1994; 4(2): 145–73

    Article  PubMed  CAS  Google Scholar 

  36. Peterson PK, Stein D, Guary DRP, et al. Prospective study of lower respiratory tract infections in an extended care nursing program: potential role of oral ciprofloxacin. Am J Med 1988 Sep; 65: 164–70

    Article  Google Scholar 

  37. Pickering TD, Gurwitz JH, Zaleznik D, et al. The appropriateness of oral fluoroquinolone-prescribing in the long-term care setting. J Am Geriatr Soc 1994; 42: 28–32

    PubMed  CAS  Google Scholar 

  38. Saltiel E, Weingarten S. Drug treatment of pneumonia in the elderly: efficacy and costs. Pharmacoeconomics 1993; 3(4): 268–75

    Article  PubMed  CAS  Google Scholar 

  39. Wilson WR. Tolerance and safety of orally administered antimicrobial agents: an important factor in the selection of drug therapy. Curr Ther Res 1994; 55 Suppl. A: 49–56

    Article  Google Scholar 

  40. Guay DRP. Sequential antimicrobial therapy: a realistic approach to cost containment. Pharmacoeconomics 1993; 3(5): 341–4

    Article  PubMed  CAS  Google Scholar 

  41. Weingarten SR, Riedinger MS, Varis G, et al. Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy. Chest 1994; 105: 1109–15

    Article  PubMed  CAS  Google Scholar 

  42. Ehrenkranz NJ, Nerenberg DE, Shultz JM, et al. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol 1992; 13: 21–32

    Article  PubMed  CAS  Google Scholar 

  43. Hirta-Dulas CAI, Stein DJ, Guay DRP, et al. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home acquired lower respiratory tract infections. J Am Geriatr Soc 1991; 39: 979–85

    Google Scholar 

  44. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6

    Article  PubMed  CAS  Google Scholar 

  45. Trenholme GM, Scmitt BA, Spear J, et al. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med 1989; 87 Suppl. 5A: 116S–8S

    Article  PubMed  CAS  Google Scholar 

  46. Dunagan WC, Woodward RS, Medoff G, et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med 1989; 87: 253–9

    Article  PubMed  CAS  Google Scholar 

  47. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296–307

    PubMed  CAS  Google Scholar 

  48. Ortiz CR, LaForce FM. Prevention of community-acquired pneumonia. Med Clin North Am 1994 Sep; 78(5): 1173–83

    PubMed  CAS  Google Scholar 

  49. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly patients. Ann Intern Med 1995; 123: 518–27

    PubMed  CAS  Google Scholar 

  50. Makela PH, Jokinen C, Pyhala R, et al. Use of vaccines for respiratory infections: strategies for influenzae and pneumo-coccal vaccines. Scand J Infect Dis 1990; Suppl. 70: 141–8

    CAS  Google Scholar 

  51. Fox RA. Treatment recommendations for respiratory tract infections associated with aging. Drugs Aging 1993; 3(1): 40–8

    Article  PubMed  CAS  Google Scholar 

  52. Anonymous. Appropriate treatment of pneumonia in the elderly may reduce costs. Drugs Ther Perspect 1993 Aug 30; 2(4): 14–6

    Article  Google Scholar 

  53. Butler JC, Breiman FR, Campbell JF, et al. Pneumococcal poly-saccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270: 1826–31

    Article  PubMed  CAS  Google Scholar 

  54. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778–84

    Article  PubMed  CAS  Google Scholar 

  55. Woo J, Ho SC, Mak YT, et al. Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial. Age Ageing 1994; 23: 40–8

    Article  PubMed  CAS  Google Scholar 

  56. Hunt C, Chakravorty NK, Annan G, et al. The clinical effects of vitamin C supplementation in elderly hospitalized patients with acute respiratory infections. Int J Vitam Nutr Res 1994; 64: 212–9

    PubMed  CAS  Google Scholar 

  57. Nelson S, Summer W, Bogby G, et al. Granulocyte colony-stimulating factor enhances pulmonary host defences in normal and ethanol treated rats. J Infect Dis 1991; 164: 901–6

    Article  PubMed  CAS  Google Scholar 

  58. Lester P, Gentry M, Prehein L. Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993; 168: 922–6

    Article  Google Scholar 

  59. Sperry S, Birdsall C. Outcomes of a pneumonia critical path. Nurs Econ 1994; 12: 332–45

    PubMed  CAS  Google Scholar 

  60. Esler R, Bentz P, Sorensen M, et al. Patient-centred pneumonia care: a case management success story. Am J Nurs 1994; 94: 34–8

    PubMed  CAS  Google Scholar 

  61. Rollins D, Thomasson C, Sperry B. Improving antibiotic delivery time to pneumonia patients: continuous quality improvement in action. J Nurs Care Qual 1994; 8: 22–31

    Article  PubMed  CAS  Google Scholar 

  62. May HM, Harrison TS, Harrison BDW. A criteria based audit of community-acquired pneumonia. Respir Med 1994; 88: 693–6

    Article  PubMed  CAS  Google Scholar 

  63. Jolley AE, Davies AJ, McLeod DT. Audit of the use of erythro-mycin in the treatment of community-acquired lower respiratory tract infections. Respir Med 1992; 86: 503–5

    Article  PubMed  CAS  Google Scholar 

  64. Dempsey CJ. Nursing home-acquired pneumonia: outcomes from a clinical process improvement program. Pharmacother-apy 1995; 15(1 Pt 2): 33S–8S

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, Dalhousie University, School of Medicine, Halifax, Nova Scotia, Canada

    Thomas J. Marrie

  2. Department of Pharmacy, Victoria General Hospital, Halifax, Nova Scotia, Canada

    Kathryn L. Slayter

  3. College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada

    Kathryn L. Slayter

Authors
  1. Thomas J. Marrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathryn L. Slayter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marrie, T.J., Slayter, K.L. Nursing Home-Acquired Pneumonia. Drugs & Aging 8, 338–348 (1996). https://doi.org/10.2165/00002512-199608050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199608050-00003

Keywords

Search

Navigation